![]() However, these formulations often fail to be useable due to systemic toxicity. The last decade has witnessed numerous efforts in developing inorganic nanoparticles capable of effectively targeting different diseases 7, 8, 9, 10, 11. The engineering flexibility provided by inorganic nanoparticles with tailorable shape, size, surface ligands and physical properties has enabled on-demand design of novel drug delivery systems, contrast agents and integrated systems for disease diagnosis and treatment 1, 2, 3, 4, 5, 6. This liquid metal-based DDS with fusible and degradable behaviour under physiological conditions provides a new strategy for engineering theranostic agents with low toxicity. Equipped with hyaluronic acid, a tumour-targeting ligand, this formulation displays enhanced chemotherapeutic inhibition towards the xenograft tumour-bearing mice. ![]() The resulting nanoparticles loaded with doxorubicin (Dox) have an average diameter of 107 nm and demonstrate the capability to fuse and subsequently degrade under a mildly acidic condition, which facilitates release of Dox in acidic endosomes after cellular internalization. This formulation can be simply produced through a sonication-mediated method with bioconjugation flexibility. ![]() We describe here a transformable liquid-metal nanomedicine, based on a core–shell nanosphere composed of a liquid-phase eutectic gallium-indium core and a thiolated polymeric shell. However, the clinical application of inorganic formulations has often been hindered by their toxicity and failure to biodegrade. To date, numerous inorganic nanocarriers have been explored for drug delivery systems (DDSs). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |